|
|
 |
|
Viewing report
|
|
|
|
U.S. Pharma Pricing Strategies: Case Studies and Future Considerations
Decision Resources, Inc., Dec 2008, Pages: 26
How should a company price its drug when generic competition is about to impact a drug class? How significant a role does price play in distinguishing drugs in a crowded marketplace? In this report, we examine three common small-molecule drug classes and six biologics to treat RA. These class and drug pricing examinations offer some unique strategic considerations regarding pricing in the face of generic erosion or a diverse market sector. We also review the changing business landscape and provide analogs that forecast the impact of generic erosion on pharma pricing strategies.
Get the Answers You Need to Shape Your Strategy
- In 2001, a generic version of the statin Mevacor entered the U.S. market. How did Mevacor’s manufacturer, Merck, respond? How did makers of other branded Statins price their drugs in the face of initial—and subsequent—generics competition? How have sales and market share of Statins - both branded and generic - changed in the face of increasing generics competition?
- Most SSRIs are available generically in the United States, but the prices of branded SSRIs have increased year over year. Why do branded SSRI manufacturers continue to raise the prices of their drugs despite the market availability of lower-cost generic alternatives? Have branded SSRI manufacturers discovered pricing strategies to retain prescription and sales volume in the face of generics competition? If so, how successful are these strategies?
- Until Wyeth’s Effexor went generic, all the branded SNRI prices steadily increased each year. How did Wyeth price its follow-on product, Effexor XR, in the wake of generic availability of Effexor? Was Wyeth’s Effexor XR pricing strategy successful? How has Eli Lilly’s SNRI Cymbalta fared in response to the availability of generic Effexor?
- The RA biologics space is a crowded and dynamic one with six drugs indicated for this indication in the United States. Does pricing play a role in competitive strategy in this market sector? If so, what pricing pitfalls must a company avoid when introducing a new biologic into this market?
Scope
- Case studies: Statins, selective serotonin reuptake inhibitors (SSRIs), serotonin-nor epinephrine. Reuptake inhibitors (SNRIs) and biologics used to treat RA.
- Tables and figures: tracing the pricing history of featured drug classes and relative pricing within drug classes.
- Expert Commentary: Barrie G. James of Pharma Strategy Consulting discusses how the current economic and political landscape will affect pharma pricing possibilities.
Customers who bought this item also bought
Can a New Antidepressant Establish Itself in a Highly Competitive Market?
The Drug Class Impact of Major Patent Expirations
European Antidepressants Markets
Antidepressants - Global Strategic Business Report
Pharmaceuticals - Global Outlook
Prescription Drugs - Global Strategic Business Report
Lipid Regulators - Global Strategic Business Report
CNS Therapeutics - Global Strategic Business Report
Major Depressive Disorder (MDD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Dyslipidemia Therapeutics - Global Strategic Business Report
|
|
|
|
